Israeli drugmaker Teva fined $519 mn in US for foreign bribes

December 22, 2016

Israeli generic drug giant Teva will pay $519 million to settle charges that it paid bribes to foreign officials to win business in Russia, Ukraine and Mexico, US officials announced Thursday.

Teva, the world's biggest company, promised to enhance its compliance program after its Russia subsidiary pleaded guilty to one count of the Foreign Corrupt Practices Act and it signed off on a deferred prosecution agreement, the Justice Department said.

"Teva and its subsidiaries paid millions of dollars in bribes to government officials in various countries, and intentionally failed to implement a system of internal controls that would prevent bribery," said assistant attorney general Leslie Caldwell.

The case included bribes by Teva Pharmaceutical Industries to a "high-ranking Russian government" official who used his authority to boost sales of the Teva multiple sclerosis drug Copaxone, resulting in more than $200 million in profits for Teva and about $65 million for the Russian official between 2010 and 2012, the Justice Department said.

In Ukraine, Teva also admitted to paying bribes to a senior government official, who agreed to promote Teva drugs. The Ukraine payments to the are from 2001 and 2011.

In Mexico, Teva's subsidiary paid to doctors employed by the Mexican government since at leat 2005, according to the Justice Department.

Teva said it commenced a probe of bribery after learning of problems from employees and US government and employees in early 2012. None of the employees involved in the wrongdoing are still at the company, it said.

"While the conduct that resulted in this investigation ended several years ago, it is both regrettable and unacceptable, and we are pleased to finally put this matter behind us," said Teva chief executive Erez Vigodman. "The Teva of today is a fundamentally different company."

Teva will pay a criminal penalty of $283 to the Department of Justice. It also agreed to pay $236 million in disgorgement to the Securities and Exchange Commission in a parallel case.

Shares of Teva rose 2.2 percent in late-morning trade to $37.18.

Explore further: Teva says US is investigating Copaxone marketing

Related Stories

Teva says US is investigating Copaxone marketing

February 10, 2014

Teva Pharmaceutical Industries said Monday the federal government is investigating its marketing of its multiple sclerosis drug Copaxone and Parkinson's disease treatment Azilect.

Teva expect to close $40.5B Allergan generic deal next week

July 27, 2016

Israeli drugmaker Teva, the largest generic drug company in the world, said Wednesday it expects to complete its $40.5 billion purchase of the generic drug business of competitor Allergan next week after federal regulators ...

Pharmaceutical giant Teva announces new CEO

January 9, 2014

Teva Pharmaceutical Industries, the world's largest maker of generic drugs, said Thursday it had appointed a new chief executive to replace Jeremy Levin, who left abruptly in October.

Teva to lift bid for Mylan: report

July 6, 2015

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Actavis UK accused of overcharging hydrocortisone drug

December 16, 2016

British regulators have accused Actavis UK of charging excessive and unfair prices after the pharmaceutical company increased the price of some hydrocortisone tablets by more than 12,000 percent.

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.